Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates
Initiated Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee
HST 004 Selected as Product Candidate for Spinal Disc Repair with IND Enabling Activities Underway
Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its clinical pipeline and other corporate developments.
“In the second quarter, we charted a more strategic course for our restorative therapeutics pipeline with a focus on orthopedic indications that we believe sit at the crossroads of pre-clinical and clinical proof-of-concept, significant commercial opportunity and unmet medical needs,” said Richard W. Pascoe, President and Chief Executive Officer. “Moreover, we believe that there is a significant value-creating opportunity for emricasan as a COVID-19 therapeutic given the positive safety and efficacy signals we reported in the recently completed Phase 1 study in mild symptomatic patients. Looking forward, we will concentrate our efforts on achieving meaningful regulatory, pre-clinical and clinical milestones for our pipeline assets in an effort to create long-term value for the benefit of patients, the healthcare community and our shareholders.”
Highlights from the Second Quarter Ended June 30, 2021 and Business Updates
- Technology and Pipeline Focus – In June 2021, we completed a strategic evaluation of our regenerative medicine platform technology and announced that our pipeline focus will be on what we believe to be high-value orthopedic indications, creating pipeline synergies and maximizing resources in an effort to further drive long-term shareholder value. Our current orthopedic development programs include HST 003 for cartilage regeneration in the knee and HST 004 for spinal disk repair. Histogen is also evaluating the potential for additional pipeline opportunities targeting other soft tissues such as the tendon and ligament.
- HST 003 – In June 2021, we initiated our Phase 1/2 clinical study of HST 003 to evaluate the safety and efficacy of human extracellular matrix (hECM) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure. We anticipate having top-line results from this study in the second quarter of 2022.
- HST 004 – We recently initiated investigational new drug application (IND) enabling activities for HST 004, a CCM solution intended to be administered through an intradiscal injection for spinal disc repair. Our initial preclinical research has shown that HST 004 stimulates stem cells from the spinal disc to proliferate and secrete aggrecan and collagen II, regenerate normal matrix and cell tissue structure and restore disc height. HST 004 was also shown to both reduce inflammation and protease activity and upregulate aggrecan production in an ex vivo spinal disc model. We anticipate filing an IND for HST 004 in the second quarter of 2022.
- Emricasan – In June 2021, we, along with our partner Amerimmune, announced positive results from the Phase 1 study of emricasan in mild symptomatic COVID-19 patients. Emricasan was shown to be safe and well-tolerated during the 14 days of dosing and at the day 45 follow up, as compared to placebo with no reports of serious adverse events. Patients who completed treatment with emricasan had a complete resolution of the symptoms most commonly associated in mild COVID-19, such as a cough, headache, and fatigue at day 7 and continued through Day 45. Patients in the placebo arm who completed the study did not experience COVID-19 symptom resolution at any time point out to day 45. We, along with our partner Amerimmune, are currently evaluating our clinical development plans for the emricasan program and expect to complete our evaluation in the third quarter of 2021.
Second Quarter 2021 Financial Highlights
Second Quarter Ended June 30, 2021 and 2020
License and Service Revenues in the second quarter of 2021 decreased nearly 100% to $5 thousand from $0.1 million in the second quarter of 2020. The decrease is primarily related to the completion of technology transfer obligations of Histogen under the Allergan Agreements. During both periods, $5 thousand of deferred revenue was recognized in relation to the Potential Future Improvements remaining performance obligation currently being amortized over the remaining 9-year patent life.
Cost of Professional Services Revenues for the three months ended June 30, 2021 and 2020 were zero and $0.1 million, respectively.
Acquired In-Process Research and Development for the three months ended June 30, 2021 and 2020 were zero and $7.1 million, respectively. Histogen incurred $7.1 million for in-process research and development acquired during the three months ended June 30, 2020 in connection with the merger.
Research and Development Expenses for the three months ended June 30, 2021 and 2020 were $2.4 million and $1.4 million, respectively. The net increase of $1.0 million for the three months ended June 30, 2021 as compared to the three months ended June 30, 2020 was primarily due to increases in expanded development costs of our product candidates partially offset by $0.2 million in qualifying expenses in connection with the Department of Defense grant and increases in personnel-related expenses.
General and Administrative Expenses for the three months ended June 30, 2021 and 2020 were $1.8 million and $1.6 million, respectively. The $0.2 million increase for the three months ended June 30, 2021 as compared to the three months ended June 30, 2020 was primarily due to increases in personnel-related expenses and insurance fees offset by other expenses, such as legal and accounting fees.
Cash and Cash Equivalents as of June 30, 2021 were $23.1 million. We believe that Histogen’s existing cash and cash equivalents and cash inflow from operations will be sufficient to meet its anticipated cash needs into the fourth quarter of 2022.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss Histogen’s future operations and its ability to successfully initiate and complete clinical trials, obtain clinical trial data and achieve regulatory milestones and related timing, including those related to the completion and reporting of top-line data for the HST 003 Phase 1/2 clinical trial for regeneration of cartilage in the knee, the completion of IND enabling activities and the anticipated filing of the HST 004 IND for spinal disc repair and the timing of providing clinical development guidance on the emricasan clinical program for the treatment of COVID-19; the nature, strategy and focus of Histogen’s business; the sufficiency of Histogen’s cash resources based on anticipated cash needs and its ability to achieve value for its stockholders, specifically given the strategic shift to orthopedic indications; the Amerimmune’s ability to further develop emricasan and achieve value for Histogen’s stockholders; and the development and commercial potential and potential benefits of any of Histogen’s product candidates, such as HST 003 and HST 004. Histogen may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Histogen’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Histogen that could differ materially from those described in or implied by the statements in this press release, including: the uncertainties associated with the clinical development and regulatory approval of Histogen’s product candidates, including potential delays in the commencement, enrollment and completion of clinical trials, such as the completion and reporting of top-line data for the HST-003 Phase 1/2 clinical trial for regeneration of cartilage in the knee, the completion of IND enabling activities and the anticipated filing of the HST 004 IND for spinal disc repair and Amerimmune’s ability to further develop emricasan for the treatment of COVID-19, including the complexity and length of studies required to commercialize emricasan for COVID-19 and potential delays in the completion of clinical trials; Histogen’s dependence on its collaboration partner, Amerimmune, to carry out the development of emricasan and the potential for delays in the timing of regulatory approval; competition in the orthopedics market, COVID-19 market and other markets in which Histogen and its collaboration partner operate; the potential that earlier clinical trials and studies of Histogen’s product candidates may not be predictive of future results; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm Histogen’s financial condition and increase its costs and expenses; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; and market and other conditions. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in Histogen’s filings with the Securities and Exchange Commission. Except as otherwise required by law, Histogen disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
HISTOGEN INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
| June 30, 2021 | December 31, 2020 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 23,140 | $ | 6,763 | ||||
| Restricted cash | 10 | 10 | ||||||
| Accounts receivable, net | 118 | 144 | ||||||
| Inventories | 61 | 300 | ||||||
| Prepaid and other assets | 1,802 | 1,183 | ||||||
| Total current assets | 25,131 | 8,400 | ||||||
| Property and equipment, net | 270 | 271 | ||||||
| Right-of-use assets | 4,291 | 4,411 | ||||||
| Other assets | 1,109 | 1,931 | ||||||
| Total assets | $ | 30,801 | $ | 15,013 | ||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 586 | $ | 539 | ||||
| Accrued liabilities | 1,523 | 1,880 | ||||||
| Current portion of lease liabilities | — | 28 | ||||||
| Payroll protection program loan, current | — | 97 | ||||||
| Financed insurance premiums, current | — | 193 | ||||||
| Current portion of deferred revenue | 19 | 48 | ||||||
| Total current liabilities | 2,128 | 2,785 | ||||||
| Payroll protection program loan, non-current | — | 369 | ||||||
| Lease liabilities, non-current | 4,587 | 4,806 | ||||||
| Non-current portion of deferred revenue | 108 | 118 | ||||||
| Other liabilities | 18 | 22 | ||||||
| Total liabilities | 6,841 | 8,100 | ||||||
| Commitments and contingencies (Note 10) | ||||||||
| Stockholders’ Equity (Deficit) | ||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2021 and December 31, 2020; no shares issued and outstanding at June 30, 2021 and December 31, 2020 | — | — | ||||||
| Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2021 and December 31, 2020; 41,729,257 and 15,030,757 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively | 4 | 1 | ||||||
| Additional paid-in capital | 95,603 | 70,561 | ||||||
| Accumulated deficit | (70,676 | ) | (62,702 | ) | ||||
| Total Histogen Inc. stockholders’ equity (deficit) | 24,931 | 7,860 | ||||||
| Noncontrolling interest | (971 | ) | (947 | ) | ||||
| Total equity (deficit) | 23,960 | 6,913 | ||||||
| Total liabilities and stockholders’ equity (deficit) | $ | 30,801 | $ | 15,013 | ||||
HISTOGEN INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product | $ | — | $ | — | $ | 306 | $ | — | ||||||||
| Grant | — | — | 113 | — | ||||||||||||
| License | 5 | 5 | 17 | 872 | ||||||||||||
| Professional services | — | 103 | — | 214 | ||||||||||||
| Total revenues | 5 | 108 | 436 | 1,086 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of product revenue | — | — | 220 | 161 | ||||||||||||
| Cost of professional services revenue | — | 89 | — | 186 | ||||||||||||
| Acquired in-process research and development | — | 7,144 | — | 7,144 | ||||||||||||
| Research and development | 2,376 | 1,437 | 4,528 | 2,828 | ||||||||||||
| General and administrative | 1,822 | 1,588 | 4,154 | 2,771 | ||||||||||||
| Total operating expenses | 4,198 | 10,258 | 8,902 | 13,090 | ||||||||||||
| Loss from operations | (4,193 | ) | (10,150 | ) | (8,466 | ) | (12,004 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income (expense), net | (2 | ) | (28 | ) | (7 | ) | (28 | ) | ||||||||
| Other income | 475 | — | 475 | — | ||||||||||||
| Total other income (expense) | 473 | (28 | ) | 468 | (28 | ) | ||||||||||
| Net loss | (3,720 | ) | (10,178 | ) | (7,998 | ) | (12,032 | ) | ||||||||
| Net loss attributable to noncontrolling interest | 16 | 10 | 24 | 20 | ||||||||||||
| Net loss attributable to common stockholders | $ | (3,704 | ) | $ | (10,168 | ) | $ | (7,974 | ) | $ | (12,012 | ) | ||||
| Net loss per share available to common stockholders, basic and diluted | $ | (0.10 | ) | $ | (1.52 | ) | $ | (0.23 | ) | $ | (2.39 | ) | ||||
| Weighted-average number of common shares outstanding used to compute net loss per share, basic and diluted | 37,196,606 | 6,710,490 | 34,399,680 | 5,026,923 | ||||||||||||
